Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
Sponsor: Quanda Liu
Summary
This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).
Official title: FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-03-31
Completion Date
2027-12-31
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Transarterial infusion chemotherapy (TAIC)
TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.
Intravenous Chemotherapy(IVC)
Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.
Locations (1)
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Xicheng, Beijing Municipality, China